Invention:
This invention is a highly novel theranostic target, extracellular nicotinamide phosphoribosyl-transferase (eNAMPT), that can afford specific detection and treatment of post-infarct inflammation-mediated myocardial injury based on an eNAMPT-neutralizing humanized monoclonal antibody (mAb).
Background:
Worldwide, cardiovascular diseases are responsible for an estimated 17.5 million deaths each year – around one in every three. The WHO estimates that, by 2030, this death toll will rise to around 24 million. eNampt acts as a pro-inflammatory cytokine contributing to cardiac hypertrophy, myocyte cell death, and interstitial fibrosis. This inflammation reaction following myocardial infarction and reperfusion has been found to be a crucial factor in ventricular remodeling, heart failure, and cardiovascular death.
This invention is a method for the detection of eNampt, selective inhibition of eNampt, prevention/treatment of cardiac disease, and detection of locations of eNampt secretion comprising an eNampt mAb.
Applications:
- All-in-one
- Accurate
- Determinant
Advantages:
- Capable of detecting eNAMPT
- Inhibiting eNAMPT
- A method of treatment
- Capable of detecting eNAMPT secretion location
